Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies
You may also be interested in...
Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent
Lilly/Icos will be able to make a 36-hour efficacy claim for the 10 mg starting dose of the erectile dysfunction treatment Cialis (tadalafil)
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive